BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

528 related articles for article (PubMed ID: 8842582)

  • 1. Shorter pill-free interval in combined oral contraceptives decreases follicular development.
    Spona J; Elstein M; Feichtinger W; Sullivan H; Lüdicke F; Müller U; Düsterberg B
    Contraception; 1996 Aug; 54(2):71-7. PubMed ID: 8842582
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Activity of the pituitary-ovarian axis in the pill-free interval during use of low-dose combined oral contraceptives.
    van Heusden AM; Fauser BC
    Contraception; 1999 Apr; 59(4):237-43. PubMed ID: 10457868
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A comparative randomized trial on the impact of two low-dose oral contraceptives on ovarian activity, cervical permeability, and endometrial receptivity.
    Rossmanith WG; Steffens D; Schramm G
    Contraception; 1997 Jul; 56(1):23-30. PubMed ID: 9306028
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Omitting the first oral contraceptive pills of the cycle does not automatically lead to ovulation.
    Elomaa K; Rolland R; Brosens I; Moorrees M; Deprest J; Tuominen J; Lähteenmäki P
    Am J Obstet Gynecol; 1998 Jul; 179(1):41-6. PubMed ID: 9704763
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ovulatory potential of preovulatory sized follicles during oral contraceptive treatment.
    Elomaa K; Lähteenmäki P
    Contraception; 1999 Nov; 60(5):275-9. PubMed ID: 10717779
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The effect of deliberate omission of Trinordiol or Microgynon on the hypothalamo-pituitary-ovarian axis.
    Smith SK; Kirkman RJ; Arce BB; McNeilly AS; Loudon NB; Baird DT
    Contraception; 1986 Nov; 34(5):513-22. PubMed ID: 3102162
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A regimen of oral contraceptives restricted to the periovulatory period may permit folliculogenesis but inhibit ovulation.
    Letterie GS
    Contraception; 1998 Jan; 57(1):39-44. PubMed ID: 9554249
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ovarian activity during regular oral contraceptive use.
    Crosignani PG; Testa G; Vegetti W; Parazzini F
    Contraception; 1996 Nov; 54(5):271-3. PubMed ID: 8934059
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Modulation of ovarian function by an oral contraceptive containing 30 micrograms ethinyl estradiol in combination with 2.00 mg dienogest.
    Spona J; Feichtinger W; Kindermann C; Moore C; Mellinger U; Walter F; Gräser T
    Contraception; 1997 Sep; 56(3):185-91. PubMed ID: 9347211
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparative profiles of reliability, cycle control and side effects of two oral contraceptive formulations containing 150 micrograms desogestrel and either 30 micrograms or 20 micrograms ethinyl oestradiol.
    Akerlund M; Røde A; Westergaard J
    Br J Obstet Gynaecol; 1993 Sep; 100(9):832-8. PubMed ID: 8218004
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ovarian activity suppression by two different low-dose triphasic oral contraceptives.
    van der Does J; Exalto N; Dieben T; Bennink HC
    Contraception; 1995 Dec; 52(6):357-61. PubMed ID: 8749599
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Serum levels of FSH, LH, estradiol-17 beta and progesterone following the administration of a combined oral contraceptive containing 20 micrograms ethinylestradiol.
    Carlström K; Lunell NO; Zador G
    Gynecol Obstet Invest; 1978; 9(6):304-11. PubMed ID: 754992
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The mechanism of action of a new low-dosed combined oral contraceptive.
    Dericks-Tan JS; Schneider K; Taubert HD
    Arch Gynecol; 1980; 229(2):107-14. PubMed ID: 6768343
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pituitary and ovarian function in women receiving hormonal contraception.
    Cohen BL; Katz M
    Contraception; 1979 Nov; 20(5):475-87. PubMed ID: 393456
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of efficacy, cycle control, and tolerability of two low-dose oral contraceptives in a multicenter clinical study.
    Endrikat J; Düsterberg B; Ruebig A; Gerlinger C; Strowitzki T
    Contraception; 1999 Nov; 60(5):269-74. PubMed ID: 10717778
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Influence of oral contraceptives on integrated secretion of gonadotropins.
    Dericks-Tan JS; Gudacker V; Taubert HD
    Contraception; 1992 Oct; 46(4):369-77. PubMed ID: 1486775
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Serum levels of d-norgestrel, luteinizing hormone, follicle-stimulating hormone, estradiol, and progesterone in women during and following ingestion of combination oral contraceptives containing dl-norgestrel.
    Brenner PF; Mishell DR; Stanczyk FZ; Goebelsmann U
    Am J Obstet Gynecol; 1977 Sep; 129(2):133-40. PubMed ID: 900174
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Laboratory criteria for menopause in women using oral contraceptives.
    Creinin MD
    Fertil Steril; 1996 Jul; 66(1):101-4. PubMed ID: 8752618
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ovulation inhibition with a combined oral contraceptive containing 1 mg micronized 17 beta-estradiol.
    Wenzl R; Bennink HC; van Beek A; Spona J; Huber J
    Fertil Steril; 1993 Oct; 60(4):616-9. PubMed ID: 8405513
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The effect of monophasic combinations of ethinyl estradiol and norethindrone on gonadotropins, androgens and sex hormone binding globulin: a randomized trial.
    Moutos D; Smith S; Zacur H
    Contraception; 1995 Aug; 52(2):105-9. PubMed ID: 8536446
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 27.